NEW YORK — Bayer has partnered with OrigiMed on the development of a next-generation sequencing-based companion diagnostic for the cancer drug larotrectinib (Vitrakvi) for the Chinese market, the companies said on Wednesday.
Larotrectinib is a tropomyosin receptor kinase inhibitor approved in the US and Europe for the treatment of solid tumors with neurotrophic receptor tyrosine kinase (NTRK) gene fusions. Bayer acquired the exclusive rights to the drug from Loxo Oncology, now an Eli Lilly subsidiary, last year.